Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Evaluate the safety pharmacokinetics and pharmacodynamics (PK/PD)of a single dose of Kamada anti-severe acute respiratory syndrome (SARS)- CoV-2 in patients hospitalized with COVID-19 caused pneumonia
Description: Record adverse events, serious adverse events, and deaths
Measure: Adverse events, serious adverse events, and deaths Time: 14 daysDescription: Record adverse events, serious adverse events, and deaths
Measure: Adverse events, serious adverse events, and deaths Time: 28 daysDescription: Measurement of the area under the curve of anti SARS CoV-2 immunoglobulin
Measure: AUC0-7 of Anti SARS CoV-2 antibodies Time: 7 daysDescription: Evaluate virus neutralization activity of patient's plasma
Measure: Neutralization activity Time: 7 daysDescription: Time patient spent in hospital
Measure: Duration of Hospitalization Time: 84 daysDescription: Score on the 6 point ordinate scale
Measure: Clinical status on the 6 point ordinate scale Time: 84 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports